Biodefense R&D: First Anthrax Vaccine Could Enter Phase II In 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
An HHS contract is supporting the development of VaxGen's recombinant anthrax vaccine. Acambis/Baxter's second-generation smallpox vaccine ACAM-2000 is in Phase II.